Scientific Committees Chair of Scientific Advisory Committee - Professor AJS Davies Our Scientific Advisory Committee is led by Professor Tony Davies, a pioneer in immunology and cancer research. Tony was the Deputy Director of the Institute of Cancer Research. Scientific Advisory Committee The Scientific Advisory Committee led by Professor Davies has UK research scientists who are leading authorities in cancer research and related subjects. Their role, under the direction of the Chairman, is to review grant proposals. Professor Margaret A Knowles Following a first degree in microbiology in Bristol and a PhD at the Imperial Cancer Research Find (now CRUK) in London, Maggie carried out postdoctoral research at the Middlesex Hospital, London before establishing her own group at the Marie Curie Research Institute in Surrey. Since 1997 she has been at the University of Leeds where her group focuses on the molecular biology of bladder cancer. Professor Colin Cooper Professor Colin Cooper is a world leading prostate cancer researcher and currently the Associate Dean (Research) for The Faculty of Medicine and Health Sciences at the University of East Anglia. He obtained his first degree at the University of Warwick and has trained at the National Institute of Health and at the Dana Farber Institute in the USA. Colin and his laboratory at the ICR have been responsible for identifying cancer genes involved in the development of sarcomas, kidney cancer and bladder cancer. He has headed initiatives that have transformed research and treatment of prostate cancer in the UK. Currently he jointly heads the International Cancer Genome Consortium(ICGC) UK Prostate Cancer Project aimed at collecting whole genome data from 250 cancers. He is also leading projects aimed at understanding the causes of prostate cancer in the hope that it will eventually be possible to prevent or slow disease progression. Professor Charlotte Bevan Charlotte Bevan is Professor of Cancer Biology at Imperial College London, where she heads prostate cancer research in the Department of Surgery Cancer. Her major research interest is in androgen signalling - how it promotes prostate cancer progression and developing new methods to inhibit it as therapy for prostate cancer. Another major focus is the role of microRNAs (small nucleic acids) in prostate cancer: their use both as therapy targets and as markers for diagnosis, prognosis and patient stratification to improve the efficacy of therapies. Dr Ian G Mills Dr Mills is a Reader at Queen's University Belfast and leads the Prostate Cancer Focus Group there as Assoociate Director of Postgraduate Research for the Cancer Centre. He is also a Honorary Senior Visiting Research Fellow at the University of Cambridge. His research focus is on stress adaptation in prostate cancer, in particular in responses to metabolic dysregulation and therapy. He is currently working on how this impacts in particular on inflammatory signalling to promote a de-differentiated/stem-like phenotype and on developing appropriate models to address this. External Advisory Committee The External Advisory Committee are completely independent eminent research scientists working outside the UK in areas relevant to the research funded by PCRC. Their role is to provide unbiased and completely objective advice to ensure that all the research PCRC funds is world class. Professor Stefan Offermanns (Germany) After finishing his medical studies, Stefan Offermanns completed his postdoctoral studies at the Free University Berlin, Germany, and the California Institute of Technology, Pasadena, California, USA. From 2000 to 2009, he held the Chair of Pharmacology at the University of Heidelberg, Germany. Since 2008 he has been a director at the Max Planck Institute for Heart and Lung Research, Germany, and a professor at the Goethe University, Frankfurt, Germany. Professor Ian Hickson FRS (Denmark) Until 2010, Ian Hickson was the Professor of Molecular Oncology and Deputy Director of the CRUK Cancer Centre at the University of Oxford. He is currently the Director of the Center for Chromosome Stability at the University of Copenhagen in Denmark. Ian Hickson is a Fellow of the Royal Society and of the Academy of Medical Sciences (UK), and a member of EMBO. Professor Simon Hayward (US) Simon W. Hayward, Ph.D. is Director of Cancer Biology at the NorthShore University HealthSystem with an academic appointment at the University of Chicago. Previously he was Professor of Urologic Surgery and Cancer Biology at Vanderbilt University Medical Center and Director of the Vanderbilt Center for Benign Urologic Diseases (VBUD). He is a past-President of the Society for Basic Urologic Research. A recent Web-of-Science citation report lists an average of 43 citations/articles and an h-index of 41. Dr. Hayward performed his doctoral work on stromal-epithelial interactions in prostate at the Imperial Cancer Research Fund laboratories in London (now Cancer Research UK). His postdoctoral work was with Dr. Gerald Cunha at UCSF. He moved to Vanderbilt in 2001. He has more than 25 years of experience with in vitro and in vivo models of prostate cancer including the use of tumor xenografting. He has internationally-recognized expertise with the tissue recombination approach. Work in his laboratory is focused upon understanding the role of the tumor microenvironment, in particular fibroblasts and inflammatory cells, in prostate cancer progression and in dissecting the systemic and local influences leading to benign prostatic hyperplasia and associated symptoms.